November 20, 2023
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
Legend Biotech Corporation (the “Company” or Legend Biotech ), through its wholly owned subsidiary, Legend Biotech Ireland Limited , entered into an exclusive, global license agreement with Novartis Pharma AG . The Company granted Novartis the rights to develop, manufacture and commercialize LB2102
August 15, 2023
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
A supplemental Biologics License Application (sBLA) was submitted to the U.S. Food and Drug Administration (FDA) and a Type II Variation Application was submitted to the European Medicines Agency (EMA) by Janssen, seeking approval of CARVYKTI ® ( ciltacabtagene autoleucel; cilta-cel) for the
May 18, 2023
Legend Biotech Reports First Quarter 2023 Results and Recent Highlights
New and updated data from the CARTITUDE Clinical Development Program and LEGEND-2 study evaluating ciltacabtagene autoleucel (cilta-cel) will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association’s (EHA) 2023 Hybrid Congress
March 30, 2023
Legend Biotech Reports Full-Year 2022 Results and Recent Highlights
CARTITUDE-4, a Phase 3 study of CARVYKTI ® (ciltacabtagene autoleucel) meets primary endpoint at the study’s first pre-specified interim analysis FDA clearance of IND application for LB2102 in Extensive Stage Small Cell Lung Cancer (SCLC) CARVYKTI ® (ciltacabtagene autoleucel) receives approval

You are about to leave